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E Petersen11, D Bunjes12, M Potter13, D Beelen14, JJ Cornelissen15, I Yakoub-Agha16, NH Russell17, J Finke18, H Schoemans19, A Vitek20,
Á Urbano-Ispízua21, D Blaise22, L Volin23, P Chevallier24, D Caballero25, H Putter3, A van Biezen3, A Henseler3, S Schönland9, N Kröger26,
J Schetelig2,4 on behalf of the Chronic Malignancy Working Party28
Even with the availability of targeted drugs, allogeneic hematopoietic cell transplantation (allo-HCT) is the only therapy with
curative potential for patients with CLL. Cure can be assessed by comparing long-term survival of patients to the matched general
population. Using data from 2589 patients who received allo-HCT between 2000 and 2010, we used landmark analyses and
methods from relative survival analysis to calculate excess mortality compared with an age-, sex- and calendar year-matched
general population. Estimated event-free survival, overall survival and non-relapse mortality (NRM) 10 years after allo-HCT were 28%
(95% confidence interval (CI), 25–31), 35% (95% CI, 32–38) and 40% (95% CI, 37–42), respectively. Patients who passed the 5-year
landmark event-free survival (N= 394) had a 79% probability (95% CI, 73–85) of surviving the subsequent 5 years without an event.
Relapse and NRM contributed equally to treatment failure. Five-year mortality for 45- and 65-year-old reference patients who were
event-free at the 5-year landmark was 8% and 47% compared with 3% and 14% in the matched general population, respectively.
The prospect of long-term disease-free survival remains an argument to consider allo-HCT for young patients with high-risk CLL,
and programs to understand and prevent late causes of failure for long-term survivors are warranted, especially for older patients.
Bone Marrow Transplantation (2017) 52, 372–380; doi:10.1038/bmt.2016.282; published online 12 December 2016
INTRODUCTION
After purine analogs (PAs) were introduced into the treatment
of patients with CLL, patients with early relapse or refractory
disease after PA-based chemoimmunotherapy were considered
high-risk patients. Further high-risk patients are characterized by
relapsed CLL harboring del(17p) or TP53 mutations. In recent
years, three new drugs received approval for the treatment of CLL:
the Bruton’s kinase inhibitor, Ibrutinib, the PI3 kinase inhibitor,
Idelalisib and the BCL2 inhibitor, Venetoclax.1,2 The three drugs
have demonstrated significant activity in patients with high-risk
CLL and are rather well tolerated, although disease control is
transient. The estimated PFS in patients with relapsed or refractory
CLL on Ibrutinib was 69% (95% confidence interval (CI), 58–78) at
30 months from the start of treatment. Yet, high-risk genetic
abnormalities retain their poor prognostic impact in the context of
treatment with Ibrutinib, and PFS of patients with del(17p) at
30 months was only 48% (95% CI, 29–65).3 On Venetoclax, 72% of
patients with del(17p) were in PFS at 12 months.1
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is
the only treatment to date with curative potential in patients with
high-risk CLL. Clearance of minimal residual disease (MRD) by
graft-versus-leukemia effects has been described in several
independent studies of patients.4,5 This observation has been
interpreted as eradication of the disease. However, cohorts of
patients who support this concept of cure by allogeneic
transplantation are relatively small.6–8
As the median age at first diagnosis of CLL is ~ 70 years, only a
small minority of patients have relapsed/refractory CLL at an age
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and in a physical condition that allows allo-HCT to be considered.
With the availability of kinase inhibitors and BCL2 inhibitors,
decision-making for patients with high-risk CLL who are eligible
for allo-HCT has become a challenging task. Patients and
physicians must weigh up risks and benefits of allo-HCT compared
with well-tolerated oral drugs with the capacity to maintain
disease control for a few years.9,10 Information on combination
therapies, cross-resistance of Ibrutinib and Idelalisib and salvage
options is just emerging.11,12 In parallel, second-generation kinase
inhibitors are being developed and show very promising results in
phase II trials.13 In this context, it is important to provide
information on the curative potential of allo-HCT. Registry data
of a large cohort can be used to estimate long-term outcomes.
Since cure cannot be assessed on the individual level, excess
mortality in long-term survivors compared with the general
population can be used as a surrogate marker for cure.
Additionally, long-term survivors themselves and their physicians
may wish to know of the prospect of cure in relation to certain
landmarks that have been passed without relapse or progression.
Here, we report on results from the analysis of long-term
survival outcomes and the estimation of excess mortality from a
large registry cohort of patients with CLL who received allo-HCT.
This information is instrumental for better patient information and
improved care for long-term survivors.
MATERIALS AND METHODS
For this study, data were extracted from the registry of the European
Society for Blood and Marrow Transplantation. All patients who received a
first allo-HCT for CLL between January 2000 and December 2010 were
included, with the exception of patients with Richter’s transformation or
with syngeneic donors.
The primary end point was overall survival (OS), defined as time since
either allo-HCT or landmark until death with surviving patients being
censored at the time of last follow-up. Landmark time-points were set at 2
and 5 years after allo-HCT. Secondary end points were event-free survival
(EFS), cumulative incidence of relapse/progression (CIR) and non-relapse
mortality (NRM), all measured either from allo-HCT or from landmark. EFS
was defined as time to death or relapse/disease progression (whichever
occurred first), with surviving patients being censored at the last time-
point reported disease-free. Relapse/progression and NRM were analyzed
together in a competing risks framework.14 At each landmark time-point,
the event-free (EF) population consisted of all patients alive without
relapse/progression before the landmark.
Next, we compared the mortality of the CLL patients to that of the
general population by means of methods from relative survival, thereby
assessing which proportion of mortality after allo-HCT could be attributed
to CLL and its treatment, and which to background mortality.15,16 First, the
survival outcomes of the landmark populations were analyzed for men and
women separately in comparison with the expected survival of a synthetic
cohort of the general population in which each patient was matched to an
artificial control with the same sex, country and age in the year of allo-HCT.
Population tables from the Human Mortality Database were used (www.
humanmortality.de). Patients originating from countries for which no
mortality data was available through this source were matched to German
controls (53 patients in the whole cohort, 16 in the 2-year landmark
population). We then studied the impact of age, sex and year of allo-HCT
on the excess hazard, defined as the difference between the observed
hazard of the CLL patients and the hazard of the matched general
population, by means of an additive Cox model for relative survival.
Model-based OS estimates with different starting times were always
illustrated for the same two reference patient groups: German men,
transplanted in 2000 at ages 45 and 65 years. They were chosen because of
the distribution of sex and country in the data set. Finally, we assessed the
contribution of death with and without prior relapse/progression to all
reported deaths in consecutive time intervals since HCT for different age
categories, by estimating the relative hazard.17
All analyses were performed in SPSS 21 and R 3.1.0 (Armonk, NY, USA),
packages ‘survival’, ‘cmprsk’, ‘relsurv’ and ‘prodlim’.
RESULTS
Patient characteristics
Data from 2589 patients were analyzed. Patient characteristics are
shown in Table 1. At allo-HCT, patients were aged between 12 and
74 years, with a median age of 55 years. The majority of patients
(74%) were male. The remission status of patients at the time of
transplantation was reported as 16% in CR, 50% in PR and 34%
with stable or progressive disease. Fifty-one percent of the
patients had an HLA-identical sibling donor. Seventy-seven
percent of patients had received reduced-intensity conditioning.
The median follow-up time since allo-HCT for patients alive
at last follow-up was 3.3 years. The number of patients still
under follow-up at the 2- and 5-year landmarks is shown in
Figure 1.
Outcomes for the whole cohort of patients
For the whole cohort of patients, OS, EFS, CIR and NRM since
allo-HCT are shown in Table 2 and Figure 2. OS decreased from
62% (95% CI, 60–64) at 2 years to 45% (95% CI, 43–48) at 5 years
and to 35% (95% CI, 32–38) at 10 years after allo-HCT. The
probability of EFS at 2 years was 49% (95% CI, 47–52) and
decreased to 28% (95% CI, 25–31) at 10 years. For this registry
cohort, NRM was reported as the major cause of treatment failure.
The NRM probability was 30% (95% CI, 28–32) at 2 years and 36%
(95% CI, 34–38) at 5 years after allo-HCT. Cumulative incidence of
relapse was 21% (95% CI, 19–22) at 2 years and 32% (95% CI,
30–35) at 10 years after allo-HCT. The latest relapse in our data was
reported as 9 years after allo-HCT. The oldest patient alive was 78
years old at last follow-up.
Outcomes for the landmark populations at 2 and 5 years
OS, EFS, CIR and NRM for patients who passed the 2- and 5-year
landmarks after allo-HCT without having experienced relapse or
progression are shown in Table 3. In patients who passed the 2-
year landmark event-free, relapse/progression and NRM continued
to occur. The cumulative incidence of relapse at 8 years after the
landmark was 24% (95% CI, 20–28) and NRM was 20% (95% CI,
16–24). The probability of being alive 10 years after allo-HCT
(8 years after the landmark) was 65% (95% CI, 60–70). For
event-free patients beyond the 5-year landmark, CIR in the next
5 years was 11% (95% CI, 7–16) and NRM was 10% (95% CI, 5–15).
The probability of being alive 10 years after allo-HCT was 83%
(95% CI, 77–90).
Excess mortality
For male patients who were event-free at the 2-year landmark,
1-year mortality of 8% contrasts with 1% in the matched general
population (Po0.001 for a comparison over time). At 10 years
after allo-HCT, survival was 63% compared with 92% in the
matched general population. One-year mortality for women in the
2-year landmark population was 7% for patients compared with
0.3% in the general population. Survival was 70% at 10 years after
allo-HCT compared with 96% in the matched general population,
respectively (see Figure 3a).
The Cox model for the excess hazard showed that sex had no
impact on the excess hazard (hazard ratio (HR) 1.0 for women
versus men, P= 0.8), whereas increasing age had a large and
significant impact (HR 1.4 for an age difference of 10 years at
allo-HCT, Po0.001) and transplantation in more recent years had
a slightly adverse impact (HR 1.3 for HCTs performed 5 years apart,
P= 0.1). The model-based estimate of 1-year mortality of 4% for a
man aged 45 years at allo-HCT who passed the 2-year landmark
contrasts with 0.4% in the matched general population. In a man
aged 65 years at allo-HCT, the corresponding numbers are 9% in
1-year mortality compared with 2% in the matched general
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population (Figure 3b, compared with Supplementary Figure S2
for women).
Next, outcomes from the 5-year landmark were investigated.
The 5-year mortality of the matched general population was 5%
compared with 17% in the landmark population (Po0.001)
(Table 3). Male patients who were event-free at the 5-year
landmark had a survival of 82% in the next 5 years in contrast with
95% in the matched general population. Five-year survival for the










Male 74 72 73




55 (12–74) 54 (12–74) 52 (23–69)
⩽ 45 years (%) 14 16 20
45–55 years 39 42 43
55–65 years 42 38 34
465 years 6 4 3
Year of allo-HCT
⩽ 2001 9 10 19
2002–2003 14 14 24
2004–2005 16 20 28
2006–2007 21 22 27
2008–2009 26 24 2
2010 14 10 0
Patient nationality
Belgium 4 3 3
Czech Republic 5 4 4
France 14 16 16
Germany 25 21 21
Great Britain 12 12 11
Italy 11 12 14
Netherlands 6 7 7




Remission status at allo-HCT (N= 2439, 94%)
CR 16 21 19
PR 50 53 51




55 (2–415) 51 (2–258) 49 (2–258)
⩽ 4 years 44 47 48
4–8 years 36 35 37
48 years 20 18 15
Karnofsky status (N= 1424, 55%)
90–100% 77 85 84
70–80% 22 14 15
⩽ 60% 1 1 1
Previous auto-HCT
No 89 89 89
Yes, 42 years before 9 9 10
Yes, ⩽ 2 years before 2 2 1
Donor match
HLA-identical sibling 51 58 66
Other donor 49 42 34
Patient–donor sex constellation
Male–male 48 47 48
Male–female 26 25 24
Female–male 15 16 15
Female–female 11 13 13










Reduced intensity 77 79 76
Myeloablative 23 21 24
Source of graft
Bone marrow 9 9 10
Peripheral blood 89 89 89
Cord blood 2 2 1
Follow-up for patients alive at last follow-up
Median (range)
(years)
3 (0–13) 5 (2–13) 7 (5–13)
Abbreviations: allo-HCT= allogeneic hematopoietic stem cell transplanta-
tion; EF= event-free population; LM= landmark. Numbers and percentages
provided in the first column indicate number of patients with data for
this variable in the full data set, if o95% of data available. aCountries
contributing o100 patients to the study.













10 years after 
alloHCT
Figure 1. Analysis populations. The number of patients in follow-up
at different time-points after allo-HCT. OS population: All patients
alive and in follow-up at the landmark; EF population: All patients in
the OS population without relapse/progression before the
landmark.
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corresponding female patients was 86% compared with 97% in
the general population.
A separate Cox model was fitted to assess the excess hazard of
this population. Sex still had no significant impact (HR 1.1 for
women versus men, P= 0.9), whereas the impact of age was
increased compared with the 2-year landmark model: HR 2.9 for a
10-year older patient at allo-HCT (Po0.001). Five-year mortality
from the 5-year landmark was 8 and 47% in male reference
patients aged 45 and 65 years at allo-HCT compared with 3 and
14% in the matched general population (Figure 3c, compared with
Supplementary Figure S2 for women).
A further Cox model for the excess hazard of mortality
since allo-HCT was fitted. This excess hazard remains above
zero until late after allo-HCT, even at 10 years after allo-HCT,
implying that excess mortality because of CLL and its
treatment does not fully vanish over time (see Supplementary
Figure S1, online only). Furthermore, it is larger for patients with
increased age at allo-HCT. Patient sex did not influence excess
mortality.
Causes of death
We analyzed causes of late NRM. In total, 19 non-relapse deaths
beyond the 5-year landmark were reported. The main cause of
death was available for 17 of the 19 patients. GVHD was
mentioned as main cause of death in 42% of patients, new
malignancies in 26% of patients, infections in 11% of patients and
miscellaneous causes in 11% of patients. Finally, we compared the
relative contribution of NRM versus death after relapse in three
time intervals. In the first 2 years after allo-HCT, 79% of deceased
patients died from NRM and 21% after having experienced relapse
or progression. The corresponding numbers for 2–5 years and
after 5 years after allo-HCT were 40 and 32% owing to NRM and
60 and 68% mortality after relapse/progression. Recalculation of
these percentages of four age groups (⩽45, 45–55, 55–65 years
and 465 years at allo-HCT) showed that after the first 2 years, the
contribution of NRM to all deaths was significantly larger for older
patients than for younger patients (see Table 4).
DISCUSSION
The aim of this study was to estimate the fraction of cured
patients with CLL after allo-HCT. Here, we report on the largest
ever published cohort of transplanted patients with CLL, with a
large number of patients with follow-up of 45 years. The 5-year
EFS of 35% in this large study fits right in the middle of the
reported range between 28 and 43% reported from smaller series
of patients.6–8,18,19 When counting from the day of allo-HCT,
28% of patients (95% CI, 25–31) maintained disease control at
10 years. For patients who passed the 2- and 5-year landmark
event-free, the fraction of patients who maintained disease
control at 10 years from allo-HCT increased to 56% (95% CI,
51–62) and 79% (95% CI, 73–85). These numbers represent
a promising perspective for patients with an otherwise
life-threatening disease.
The cohort of patients in this study is remarkably different
compared with previously published studies on long-term survival
after allo-HCT for other diseases. First, the median age at allo-HCT
was 55 years as compared with o35 years in cohorts of long-term
survivors who were reported so far.20–23 Second, in our series the
percentage of male patients was higher (74%), a feature specific
to CLL.
Older age and male sex are linked to higher mortality, and thus,
expectedly, the survival probabilities of the landmark populations
of CLL patients are not as high as reported from those studies,
which analyzed patients whose median age was 20 years lesser at
allo-HCT. For example, the 2-year event-free landmark population
of CLL patients in our study had a 10-year survival of 65% (95% CI,
60–70) compared with 84% reported by Wingard et al.22 in
lymphoma patients with a median age of 34 years at allo-HCT.
Table 2. Overall and event-free survival, cumulative incidences of relapse/progression and non-relapse mortality for patients with CLL at 1, 2, 5 and











1 year 71 (69–73) 62 (60–64) 14 (13–15) 24 (23–26)
2 years 62 (60–64) 49 (47–52) 21 (19–22) 30 (28–32)
5 years 45 (43–48) 35 (33–37) 29 (27–30) 36 (34–38)
10 years 35 (32–38) 28 (25–31) 32 (30–35) 40 (37–42)
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b Non-relapse mortality (NRM) and cumulative incidence of  
relapse/progression (CIR) of all patients from alloHCT  
Overall survival (OS) of all patients from alloHCT 
Figure 2. OS, NRM and CIR of all patients from allo-HCT.
(a) Kaplan–Meier plot for OS of the whole cohort with 95% CIs.
The survival probability of the age-, sex-, country- and calendar
year-matched general population is shown by the dashed black line.
(b) CIR and NRM. A full color version of this figure is available at the
Bone Marrow Transplantation journal online.
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To interpret this huge difference, the effect of the disease
history and allo-HCT needs to be separated carefully from the
expected ‘background’ mortality in the corresponding general
population.
We calculated excess mortality compared with age-, sex-,
country- and calendar year-matched controls. The advantage of
using an additive Cox model for relative survival compared with
the standardized incidence ratio—which is usually used for this
purpose—is that the effect of risk factors can be determined and
that the changes in excess hazard over time are taken into
account. For example, for 65-year-old male patients who passed
the 5-year post-allo-HCT landmark event-free, the 5-year mortality
was 3.3 times (47% compared with 14%) as high as their matched
controls. Reasons for excess mortality are late complications of CLL
treatment before allo-HCT, mortality associated with allo-HCT and
relapse of CLL. Comorbidity not related to CLL may also have an
impact on mortality. The hematopoietic cell transplantation-
specific comorbidity index as published in 2005 is a tool for
classification of such information.24 Unfortunately, this index was
not reported to the European Society for Blood and Marrow
Transplantation registry for patients transplanted between
2000 and 2010. Thus, unfortunately, the degree of measurable
comorbidity at allo-HCT cannot be displayed meticulously.
Excess mortality was lower for younger patients (see Figure 3c).
For example, for a 45-year-old male patient who passed the
5-year landmark, excess mortality was 5% for the next 5 years.
NRM was the main cause of death in the first 2 years following
allo-HCT, whereas CLL relapse was the predominant cause of
death approximately from this landmark onwards (Table 4).
However, NRM also accounted for a substantial fraction of
mortality later on as shown by others before.20,22,23 For example,
for the 5-year EF population, the incidence of NRM in the next
5 years was 10% (95% CI, 5–15) compared with 5% mortality of the
matched population. This demonstrates that a substantial
proportion of late mortality was related to the transplant
procedure or the treatment of CLL before allo-HCT.
It has been reported before that mortality remains higher
compared with that of matched controls, even for patients who
passed the 10-year landmark after allo-HCT.20,22,23 Interestingly, in
our cohort excess mortality increased with age and the impact of
age was even more pronounced for late mortality. As this study
represents the first report on long-term survivors after allo-HCT in
older patients, it is unknown whether this finding is specific for
patients with CLL. Several groups have reported on a higher risk of
cardiovascular events after allo-HCT.25–27 In our cohort, GVHD and
infections were still the most frequently reported main causes of
late NRM. It has been demonstrated before that adjudication of
causes of NRM is a complex undertaking and we cannot exclude
that causes of death were attributed to GVHD, although other
chronic conditions were causal or MRD had reappeared.28
Thus, detailed information on late causes of mortality is important
and therefore our findings provide strong motivation for the
implementation of long-term follow-up programs.29–31
The cumulative incidence of relapse of 29% at 5 years in this
cohort study fits well with previously published data ranging from
17 to 46%.6–8,18 A common pattern observed in most studies is
that reduced-intensity conditioning is associated with higher
relapse rates compared with myeloablative regimens. Yet, a
consistent effect of conditioning intensity on OS has not been
demonstrated for CLL.18,32 Late relapses occurred in all of these
studies. In our registry analysis, very late relapses after allo-HCT
remained an important cause of treatment failure. Data on MRD at
the landmark time-points were not available and one may
speculate that patients with an MRD-negative CR at the landmark
time-points have a better prognosis than the EF populations
shown in this analysis. Still, the relapse rate was remarkably high.
Two lessons can be learned with respect to graft-versus-leukemia
effects from this observation. First, immunologic effector mechan-
isms fail to fully eradicate the disease and rather implement
control of growth in a substantial proportion of patients. Second,
late immunologic events may release CLL proliferation: this could
be explained either by clonal evolution of CLL cells leading to
immune escape or by a state of anergy of the donor immune
system towards the leukemia.33
Which clinical consequences can be delineated from these results?
First, monitoring for relapse after allo-HCT remains an important task.
Patients with relapse benefit from salvage therapy and still have a
relatively good prognosis.34,35 For example, Ibrutinib represents an
appealing treatment option with an attractive risk–benefit profile.36
In a recently published series, the overall response rate in 16 patients
with CLL who experienced relapse after allo-HCT was 88% and the
PFS rate at 2 years was 77%.37 Venetoclax, a BCL2 inhibitor with
great activity in patients with relapsed/refractory CLL, has recently
been approved by the Food and Drug Administration and may
become another option for patients who relapse after allo-HCT.1 Yet,
data on the use of Venetoclax in the post-transplantation setting are
still lacking. Owing to the favorable risk–benefit ratio, both Ibrutinib
and Venetoclax might even become suitable to treat relapsing CLL
at a level of MRD. Second, our findings should provide motivation for
improved care for long-term survivors. Elderly patients in particular
may need special follow-up programs to counteract the increased
hazard of death. Recommendations for the care of long-term
survivors have been published in recent years and a variety of tools
are available including educational material for patients such
as the Transplant Guidelines Application (https://bethematch.org/
for-patients-and-families/support-and-resources/).29,30 It is likely that
the implementation of structured follow-up programs and better
patient education will be instrumental to further reduce morbidity
and mortality after allo-HCT. Finally, the prospect of long-term
disease-free survival remains a valid argument for carefully
Table 3. Overall and event-free survival, cumulative incidences of relapse/progression and non-relapse mortality for the 2- and 5-year LM













2-Year event-free LM population
3 1 93 (91–94) 86 (84–89) 7 (5–9) 7 (5–8)
5 3 81 (78–84) 71 (68–75) 16 (13–18) 13 (11–15)
10 8 65 (60–70) 56 (51–62) 24 (20–28) 20 (16–24)
5-Year event-free LM population
6 1 96 (94–98) 92 (89–95) 5 (2–7) 3 (1–5)
10 5 83 (77–90) 79 (73–85) 11 (7–16) 10 (5–15)
Abbreviations: allo-HCT= allogeneic hematopoietic stem cell transplantation; CI= confidence interval; LM= landmark.
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considering allo-HCT in high-risk CLL, balancing individual disease-
specific and transplant-related risk factors, options to participate in
clinical trials with new drugs, reimbursement of Venetoclax, Ibrutinib
and Idelalisib, and the patient’s preferences.9
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGEMENTS
We thank Maja Pohar Perme (Institute for Biostatistics and Medical Informatics,
University of Ljubljana, Ljubljana, Slovenia) for help with the software. Further, we are
very grateful to Emili Montserrat who gave substantial input and critically revised the
manuscript.
THE CHRONIC MALIGNANCY WORKING PARTY MEMBERS
Gerhard Ehninger, Universitaetsklinikum Dresden, Dresden, Germany; Dietger
Niederwieser, University Hospital Leipzig, Leipzig, Germany; Pavel Jindra,
Charles University Hospital, Pilsen, Czech Republic; Henrik Sengeloev, Rigshos-
pitalet, Copenhagen, Denmark; Martin Gramatzki, University Hospital Schleswig-
Holstein Kiel Campus, Kiel, Germany; Peter Dreger, University of Heidelberg,
Heidelberg, Germany; Eefke Petersen, University Medical Centre, Utrecht, The
Netherlands; Donald Bunjes, Universitätsklinikum Ulm, Ulm, Germany; Michael
Potter, Royal Marsden Hospital, London, UK; Dietrich Beelen, University Hospital,
Essen, Germany; Jan Cornelissen, Erasmus MC-Daniel den Hoed Cancer Centre,
Rotterdam, The Netherlands; Ibrahim Yakoub-Agha, Hôpital HURIEZ, Lille,
FranceNigel Russell, Nottingham City Hospital, Nottingham, UK; Jürgen Finke,
University of Freiburg, Freiburg, Germany; Hélène Schoemans, University
Hospital Gasthuisberg, Leuven, Belgium; Antonin Vitek, Institute of Hematology
and Blood Transfusion, Prague, Czech Republic; Alvaro Urbano Ispizua, Hospital
Clinic, Barcelona, Spain; Didier Blaise, Institut Paoli Calmettes, Marseille,
FranceLiisa Volin, HUCH Comprehensive Cancer Center, Helsinki, Finland;
Renate Arnold, Charité Universitätsmedizin Berlin, Berlin, Germany; Patrice
Chevallier, CHU Nantes, Nantes, France; Dolores Caballero, Hospital Clínico,
Salamanca, Spain; Joan Hendrik Veelken, Leiden University Hospital, Leiden, The
Netherlands; Ghulam Mufti, GKT School of Medicine, London, UK; Noel Milpied,
Hôpital Haut-leveque, Pessac, France; Bruno Benedetto, AOU Citta della Salute e
della Scienza di Torino, Torino, Italy; Michel Schaap, Radboud University,
Nijmegen Medical Centre, Nijmegen, The Netherlands; Véronique Leblond,
Universite Paris IV, Hopital la Pitié-Salpêtrière, Paris, France; Manos Nikolousis,
Birmingham Heartlands Hospital, Birmingham, UK; Michael Hallek, University
of Cologne, Cologne, Germany; Jakob Passweg, University Hospital, Basel,
Table 4. Contribution of death with and without prior relapse/












0–2 ⩽ 45 105 76
45–55 325 77
55–65 436 81
465 59 81 0.2
2–5 ⩽ 45 37 19
45–55 97 42
55–65 115 45
465 16 44 0.02
45 ⩽45 6 0
45–55 28 21
55–65 32 47
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Abbreviations: allo-HCT= allogeneic hematopoietic stem cell transplanta-
tion; NA, not applicable; NRM, non-relapse mortality. aThirteen patients at
risk, no dead reported. ‘Number of deaths’ indicates the reported number
of deaths in the data set in the indicated age group and time period. The
fourth column gives the proportion of NRM deaths among all observed
deaths. The contribution of death after relapse/progression can be
calculated as 100 minus this number. The last column contains P-values
for the χ2 test for trend in proportions, testing within each time interval the
association between age and proportion of NRM.
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Figure 3. OS compared with matched general population. OS is
shown in landmark populations of patients with CLL who were alive
and event-free at the 2- and 5-year landmark after hematopoietic
cell transplantation (solid lines). This outcome is contrasted with
survival of the age-, sex-, country- and calendar year-matched
general population (dashed lines). (a) OS since the 2-year landmark
for male and female patients and the corresponding outcome of the
general population. (b and c) OS since the 2- and 5-year landmark
for male reference patients of ages 45 years and 65 years at allo-HCT
based on a Cox regression model for relative survival. A full color
version of this figure is available at the Bone Marrow Transplantation
journal online.
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